Peptide PilotPeptide Pilot

Dose calculator

Melanotan-2 dose calculator

Convert any Melanotan-2 dose into syringe units in real time, pre-filled with a 10 mg / 2 mL example.

Download Peptide PilotiPhone · Free to download

Draw on a U-100 syringe

10.0 units

Volume to draw

0.100 mL

Melanotan 2 is a peptide people inject to develop a deeper tan with less sun exposure by activating the body's own pigment-producing cells. It binds to melanocortin receptors that signal melanocytes to make more melanin, and it can also trigger libido effects as a side effect. In small studies, users developed visibly darker skin within 2–4 weeks of consistent low-dose use. This page covers reconstitution math and how people typically log a loading-then-maintenance schedule.

How the Melanotan-2 dose calculator works

This calculator answers a simple question: given the concentration of the Melanotan-2 solution already in your vial, how many syringe units does today's dose work out to? It is the second half of the reconstitution math — the first half locks in concentration, this one converts any dose mg or mcg into a clean unit count.

The formula is volume in mL equals dose mg divided by concentration mg/mL, then volume times one hundred to get units on a U-100 insulin syringe. With a 5 mg/mL Melanotan-2 solution and a 0.5 mg dose, the draw is 0.10 mL or about 10 units. Type any other dose and the unit count updates in real time — no spreadsheets, no guesswork.

Inputs that genuinely matter: concentration (which only changes when you reconstitute a new vial) and dose mass. Syringe type matters too, but only because U-100 vs U-40 changes the multiplier — almost every modern insulin syringe is U-100, which is why the math defaults to that. Edge cases worth flagging: switching from mcg to mg without checking the input unit, or carrying yesterday's unit count over to a new vial that was reconstituted with a different volume of BAC water.

Most people use this calculator at two moments: when titrating a dose up or down, and when prepping a single dose before injection. The output is meant to be checked against the syringe before drawing — read the markings, confirm the unit count, then draw. The calculator is fast precisely so you can do that check every time without it feeling like a chore.

How Melanotan-2 dosing is tracked

Loading-phase protocols are typically daily; maintenance-phase protocols are less frequent. Recording the transition from loading to maintenance explicitly in the log is what makes the phase change auditable later.

A common protocol structure documented in personal logs for Melanotan-2 involves two distinct phases: a 'loading' phase and a 'maintenance' phase. The initial loading phase typically consists of small, frequently administered doses. Users may plan to schedule these administrations daily or every other day over a period of 7 to 21 days. The objective from a data-logging perspective is not simply to document the passage of time, but to track the cumulative dose required to reach a specific, observable endpoint. Meticulously recording each administration during this period allows for a granular analysis of the dose-response relationship unique to the individual.

Upon reaching the desired response level, users typically transition to a maintenance phase. This involves adjusting the schedule to a less frequent cadence, such as once or twice per week, to sustain the observed state. The dose amount may also be adjusted during this phase. Logging the specific date of this transition is one of the most critical data entry points for any long-term tracking plan. This marker allows calculation tools to properly attribute dosage and observations to either the initial accumulation period or the subsequent sustainment period, providing a clear and auditable record for personal review.

Melanotan-2 mechanism in plain English

Melanotan-2 binds to multiple melanocortin receptors. Personal logs pair the dose history with whatever the protocol targets — pigmentation notes, response ratings, or general wellbeing tracking.

The mechanism of Melanotan-2 is characterized by its action as a non-selective agonist for a range of melanocortin receptors (MCRs). The melanocortin system is comprised of five distinct G-protein coupled receptors, labeled MC1R through MC5R, which are distributed differently throughout the body and mediate different physiological processes. While native α-MSH also interacts with several of these receptors, Melanotan-2 binds with high affinity to MC1R, MC3R, MC4R, and MC5R. This lack of selectivity is a defining feature and is responsible for the broad spectrum of effects observed in research and documented in personal-tracking logs.

The multi-receptor binding profile of Melanotan-2 is what distinguishes it from other melanocortin peptides like Melanotan-1 and bremelanotide (PT-141). MC1R is most famously studied for its role in regulating skin pigmentation and inflammation. MC3R and MC4R are heavily concentrated in the central nervous system and are subjects of intense study regarding their roles in energy homeostasis, appetite regulation, and sexual function. MC5R is studied for its function in regulating exocrine gland secretion. Because Melanotan-2 interacts with this entire suite of receptors, its observed response profile is more complex and wide-ranging than that of a more selective agonist.

Common Melanotan-2 dose mistakes

  • Continuing a loading-phase dose into what should have been the maintenance phase because no transition was recorded.
  • Reading 0.5 mg as 10 units regardless of vial concentration. The unit count depends on diluent volume.
  • Reusing the previous vial's unit count after changing diluent volume.
  • Letting reconstituted Melanotan-2 warm to room temperature on travel days.
  • Not writing the reconstitution date on the vial.
  • Assuming a linear response to each individual dose rather than scheduling and tracking the cumulative dose over a defined loading phase.
  • Failing to document an adjusted, higher-volume reconstitution plan, leading to significant errors in dose calculation when converting from units to milligrams.
  • Interpreting observed responses through the lens of a single-receptor mechanism instead of accounting for the established multi-receptor binding profile of Melanotan-2.

Frequently asked questions about Melanotan-2 dose

How is Melanotan-2 reconstituted?
Add a measured volume of bacteriostatic water through the rubber stopper and swirl gently until the powder fully dissolves. A 10 mg vial with 2 mL of BAC water gives a concentration of 5 mg per mL.
How many units of Melanotan-2 are in 0.5 mg?
On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 0.5 mg is exactly 10 units on a U-100 syringe. With 4 mL of diluent, the same dose is 20 units.
Is Melanotan-2 dosed in loading and maintenance phases?
Many personal protocols use a daily loading phase followed by a less-frequent maintenance phase. Recording the date of the phase transition is what makes the timeline auditable later.
How long does a 10 mg Melanotan-2 vial last?
At a 0.5 mg daily dose, a 10 mg vial provides 20 doses — about 2.9 weeks of daily supply.
Does Melanotan-2 need to be refrigerated?
Lyophilized powder is typically stored refrigerated, and the reconstituted vial is kept refrigerated and used within several weeks.
How is Melanotan-2 different from Melanotan-1?
Both are synthetic alpha-MSH analogs. Melanotan-1 is closer in structure to native alpha-MSH and acts more selectively; Melanotan-2 is a shorter, more potent analog that binds multiple melanocortin receptors.
How does Melanotan-2 differ structurally and functionally from Melanotan-1?
The primary structural difference is that Melanotan-2 is a cyclic peptide, while Melanotan-1 is linear. This cyclization gives Melanotan-2 enhanced stability and a longer biological half-life. Functionally, this leads to a key difference in receptor selectivity; Melanotan-1 is highly selective for the MC1 receptor, whereas Melanotan-2 is a non-selective agonist that binds strongly to MC1R, MC3R, MC4R, and MC5R. This broader receptor engagement is why the two peptides are studied for different purposes and why tracking logs often document very different observational profiles.
What is the relationship between Melanotan-2 and PT-141 (bremelanotide)?
PT-141, also known as bremelanotide, is an active metabolite of Melanotan-2. It is a smaller peptide fragment corresponding to the core sequence of Melanotan-2 but lacks the specific amino acid residues that confer high affinity for the MC1 receptor. As a result, PT-141 is a more selective agonist, primarily targeting the MC3 and MC4 receptors. This difference in receptor targeting is why PT-141 is studied for effects related to sexual function and appetite, largely separate from the pigmentation effects associated with MC1R activation.
Why is documenting a 'loading phase' versus a 'maintenance phase' so important for tracking?
Documenting these two phases separately is critical for accurate data analysis. The loading phase is the initial period of dose accumulation where the goal is to reach a state of receptor saturation that produces a consistent, observable response. Tracking this phase allows a user to calculate the *total cumulative dose* required to reach their desired endpoint. The maintenance phase is a subsequent period of less frequent administration designed to sustain that state. Separating the two in a log creates an auditable record that clarifies the dose-response relationship.

Related on Peptide Pilot

Log every Melanotan-2 dose in the app

Download on the App Store
Get the App